行情

XENT

XENT

Intersect ENT
NASDAQ

实时行情|Nasdaq Last Sale

20.84
-0.55
-2.57%
交易中 12:30 08/11 EDT
开盘
21.50
昨收
21.39
最高
21.69
最低
20.75
成交量
12.53万
成交额
--
52周最高
31.46
52周最低
5.97
市值
6.82亿
市盈率(TTM)
-10.9133
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测XENT价格均价为18.93,最高价位30.00,最低价为10.00。

EPS

XENT 新闻

更多
Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates
Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.
Zacks · 6天前
Intersect ENT shares are trading higher after the company reported better-than-expected Q2 sales results.
Benzinga · 6天前
Intersect ENT EPS misses by $0.09, beats on revenue
Intersect ENT (NASDAQ:XENT): Q2 Non-GAAP EPS of -$0.65 misses by $0.09; GAAP EPS of -$0.71 misses by $0.13. Revenue of $9.78M (-63.3% Y/Y) beats by $1.91M.
seekingalpha · 08/04 16:06
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Intersect ENT (XENT) delivered earnings and revenue surprises of -30.00% and 24.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 12:35
Intersect ENT Q2 Adj. EPS $(0.65) Misses $(0.56) Estimate, Sales $9.78M Beat $5.41M Estimate
Intersect ENT (NASDAQ:XENT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.56) by 16.07 percent. This is a 80.56 percent decrease over losses of $(0.36) per share from
Benzinga · 08/04 11:19
Intersect ENT Reports Second Quarter 2020 Financial Results
Intersect ENT Reports Second Quarter 2020 Financial Results
Business Wire · 08/04 11:00
Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Did Hedge Funds Make The Right Call On Intersect ENT Inc (XENT) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 07/28 15:11

所属板块

医疗设备、用品及经销
+0.35%
医疗设备和用品
+0.18%

热门股票

代码
价格
涨跌幅

XENT 简况

Intersect ENT, Inc.是一家商业级药物装置公司。该公司为耳鼻喉(ENT)疾病患者开发药物。该公司开发一种药物释放生物可吸收植入技术,使治疗药物可以靶向与持续释放。该公司的商业产品PROPEL和PROPEL微型药物释放植入物用于接受鼻内腔手术以治疗慢性鼻窦炎的患者。该公司正在建立一个基于其药物释放生物可吸收植入技术的产品组合,旨在为处于连续照护的慢性鼻窦炎患者提供局部给药治疗。该公司的类固醇释放植入物是用于慢性鼻窦炎患者的药物释放植入物。PROPEL微型植入物是PROPEL的较小版本,并由相同的生物可吸收聚合物纤维、相同的药物释放涂层和其他设计特征制造。该公司还开发类固醇释放植入物NOVA。
展开

微牛提供Intersect ENT Inc(NASDAQ-XENT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的XENT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易XENT股票基本功能。